Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Clinical trial NCT05050630 · UNKNOWN

Trial details

NCT number: NCT05050630
Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Age Range ≥16 Years, Gender Unlimited Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma ECOG Physical Status Score is 0-3 The Researchers Judged That Life Expectancy Was at Least Three Months Understand and Voluntarily Sign Written Informed Consent

Start date: 2021-08-01
Primary completion: 2022-07-30
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.